Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01970865 · ClinicalTrials.gov registry record · Phase 1
A Study Of PF-06463922 An ALK/ROS1 Inhibitor In Patients With Advanced Non Small Cell Lung Cancer With Specific Molecular Alterations
A Phase 1 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 364
- Enrollment target
NCT01970865 is a Phase 1 study that has completed, run by Pfizer. The registered enrollment target is 364 participants.
The verdict
NCT01970865, a Phase 1 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 364 participants
- Enrollment target
Study Summary
Phase 1 and 2 trial to study the safety, pharmacokinetics, pharmacodynamics, patient reported outcomes and efficacy of PF-06463922 in ALK + advanced non-small cell lung cancer patients and ROS1+ advanced non small cell lung cancer patients .
Interventions
- DRUG Crizotinib
- DRUG PF-06463922
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 364 participants |
| Start Date | 2014-01-08 |
| Est. Completion | 2023-05-24 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01970865
The ClinicalTrials.gov registry entry for NCT01970865 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 364 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Crizotinib is the first listed.
NCT01970865 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01970865 about?
NCT01970865 is a clinical study titled "A Study Of PF-06463922 An ALK/ROS1 Inhibitor In Patients With Advanced Non Small Cell Lung Cancer With Specific Molecular Alterations". Phase 1 and 2 trial to study the safety, pharmacokinetics, pharmacodynamics, patient reported outcomes and efficacy of PF-06463922 in ALK + advanced non-small cell lung cancer patients and ROS1+ advanced non small cell lung cancer patients .
What is the current status of trial NCT01970865?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 364 participants. The study started on 2014-01-08. Estimated completion is 2023-05-24.
What interventions are being tested in trial NCT01970865?
The interventions under investigation include: Crizotinib (DRUG), PF-06463922 (DRUG).
Who is sponsoring clinical trial NCT01970865?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.